International Psoriasis Council

Advancing Knowledge. Improving Care.

Advancing Knowledge. Improving Care.

Marcus Schmitt-Egenolf





Professor of dermatovenereology & distinguished teacher, Department of public health & clinical medicine
Umeå University
Professor Marcus Schmitt-Egenolf is a Professer of Dermatology Umeå University and an affiliated researcher at Karolinska Institute, Sweden. He studied in Frankfurt, Vienna, and Edmonton. After his MD-thesis (psoriasis-immunogenetics) under the guidance of Enno Christophers and Wolfram Sterry, the German Research Council funded his postdoctoral research with Georg Stingl in Vienna. After that, he became a specialist at the Charité, Berlin. Following his PhD, he became an associate professor in 2000 at the Norwegian University of Science and Technology (NTNU), Trondheim. Since 2002 he has worked in Umeå, where he was appointed head of dermatovenereology in 2012, then full professor and distinguished teacher in 2014.

Marcus’ research centers on melanoma and psoriasis. He initiated the Swedish psoriasis registry in 2006 and is part of the editorial boards of several journals and associate editor at the British Journal of Dermatology. Marcus is a member of the IPC’s psoriasis severity working group, a responsible dermatologist for the national psoriasis guidelines from the Swedish Board of Health and Welfare, and a senior advisor for several other public agencies and organizations.
Last Updated:

Areas of Interest

Real world evidence.

IPC Committees / Groups

Disease Severity Working Group

Languages Spoken

English, German, Norwegian, Swedish

Involvement with Other Organization(s)

Member of the Scientific Advisory Board Swedish patient organisation PSO; responsible dermatologist in the project management for the national guidelines for psoriasis at the Swedish Board of Health and Welfare; Senior advisor at Swedish Board of Health and Welfare (SoS), Swedish Agency for Health Technology Assessment (SBU), Medical Products Agency (MPA), and Swedish Dental and Pharmaceutical Benefits Agency (TLV).